Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» NASH
NASH
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
Endpoints
Wed, 03/22/23 - 10:05 am
89Bio
NASH
clinical trials
gozafermin
Akero Therapeutics
FDA schedules adcomms for Entasis' antimicrobial treatment, Intercept's NASH hopeful
Endpoints
Mon, 03/13/23 - 10:19 am
FDA
Entasis
Intercept Pharma
sulbactam-durlobactam
obeticholic acid
NASH
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Novartis backs away from NASH, furthering its research revamp
BioPharma Dive
Sun, 02/26/23 - 10:16 pm
Novartis
NASH
Pliant Therapeutics
PLN-1474
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
Wed, 02/15/23 - 06:08 pm
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
Nimbus hopes to strike thrice
EP Vantage
Tue, 02/7/23 - 11:08 am
Nimbus Therapeutics
NASH
firsocostat
FDA accepts Intercept’s resubmitted NDA for obeticholic acid
Clinical Trials Arena
Thu, 01/26/23 - 10:51 am
FDA
Intercept Pharma
OCA
obeticholic acid
NASH
By summer solstice, we'll know the fate of Intercept's NASH drug
Endpoints
Thu, 01/19/23 - 09:39 am
Intercept Pharmaceuticals
FDA
NASH
obeticholic acid
OCA
Madrigal shares triple on positive NASH study results
BioPharma Dive
Mon, 12/19/22 - 12:22 pm
Madrigal Pharmaceuticals
clinical trials
NASH
resmetirom
Axcella axes NASH program, 85% of staff in last-ditch focus on long COVID
Fierce Biotech
Thu, 12/15/22 - 11:18 am
Axcella Therapeutics
NASH
layoffs
COVID-19
Long COVID
NASH: Wall Street’s Forgotten Mega Blockbuster Indication
BioSpace
Mon, 12/12/22 - 10:13 am
NASH
Intercept Pharma
Novo Nordisk
Madrigal Pharmaceuticals
Inventiva
Galmed Pharmaceuticals
Pfizer discards eczema, NASH and breast cancer programs in early-phase clean-out
Fierce Biotech
Tue, 11/1/22 - 12:09 pm
Pfizer
R&D
NASH
breast cancer
eczema
Ocaliva fails NASH trial just as Intercept charts path toward FDA application
Fierce Pharma
Fri, 09/30/22 - 12:31 pm
Intercept Pharma
NASH
obeticholic acid
Ocaliva
clinical trials
FDA
With cash dwindling, Axcella shares look at blinded NASH data
Fierce Biotech
Thu, 09/29/22 - 10:11 am
Axcella
NASH
clinical trials
AXA1125
Biotech’s near-term key catalysts
EP Vantage
Thu, 09/29/22 - 09:45 am
Biogen
Eisai
Alzheimer's disease
Arrowhead Pharmaceuticals
Takeda
RNAi
Madrigal
NASH
Ascendis
FDA
Altimmune sees phase 1 success in tricky NASH indication with GLP-1 agonist
Fierce Biotech
Wed, 09/14/22 - 08:06 pm
Altimmune
NASH
clinical trials
pemvidutide
Oramed phase 2 insulin drug data ‘paint an exciting picture’ in rocky NASH landscape
Fierce Biotech
Tue, 09/13/22 - 07:56 pm
Oramed
NASH
diabetes
Pfizer
insulin
clinical trials
ORMD-0801
Akero hits endpoints in midphase NASH trial, linking candidate to improvements in fibrosis
Fierce Biotech
Tue, 09/13/22 - 10:40 am
Akero Therapeuticsw
NASH
liver fibrosis
clinical trials
efruxifermin
Hepion screens first subject in Phase IIb trial of NASH drug
Clinical Trials Arena
Thu, 09/1/22 - 10:42 am
Hepion Pharmaceuticals
NASH
clinical trials
rencofilstat
A pharmaceutical jack of all trades? Novo CEO touts semaglutide's potential in NASH, Alzheimer's and its hot start in obesity
Fierce Pharma
Mon, 08/29/22 - 10:40 am
Novo Nordisk
semaglutide
NASH
Alzheimer's disease
Saxenda
obesity
Pages
« first
‹ previous
1
2
3
4
5
6
7
8
9
…
next ›
last »